Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jul 2023, 16:30.
RA CAPITAL MANAGEMENT, L.P. - 05 Jul 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)
- Reporting relationship
- Director
- Issuer ticker
- BDTX
- Reported as of
- 05 Jul 2023
- Net transaction value
- +$4,679,250
- SEC form
- 4
- Accepted by SEC
- 07 Jul 2023, 16:30:27 UTC
- Prior SEC filing
- 28 Jun 2023
- Next SEC filing
- 21 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RA CAPITAL MANAGEMENT, L.P. filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 07 Jul 2023.
Change
- Previous filing in this sequence was filed on 28 Jun 2023.
- Current net transaction value: +$4,679,250.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BDTX
transaction
Common Stock
Purchase
- Transaction value
- $4,679,250
- Shares
- +935,850
- Change %
- +41%
- Price
- $5.00
- Shares after
- 3,213,828
- Date
- 05 Jul 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
BDTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 311,926
- Date
- 05 Jul 2023
- Ownership
- See Footnotes
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on June 30, 2023.
Footnote F2
Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
Footnote F3
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Footnote F4
Held directly by the Nexus Fund.
SEC remarks
Mr. Rajeev Shah, a Managing Partner of the Adviser, serves on the Issuer's board of directors.